Adc Therapeutics

$16.78 0.00% ($0.00)
  • 1D
  • 1W
  • 1M
  • 1Y
  • 5Y
  • YTD

Get ready to invest


About Adc Therapeutics

ADC Therapeutics SA is a Switzerland-based clinical-stage oncology drug discovery and development company. It develops antibody drug conjugates (ADCs) for the treatment of both solid and hematological cancers. It employs monoclonal antibodies specific to particular tumor antigens conjugated to a class of pyrrolobenzodiazepine (PBD)-based warheads to selectively target and kill cancer cells. The Company has multiple PBD-based ADCs in ongoing clinical trials, ranging from first in human to pivotal Phase II clinical trials, and numerous preclinical ADCs in development. Its main drug candidates are ADCT-301 for the treatment of lymphoma and leukemia and ADCT-402 for the treatment of non-Hodgkin’s lymphoma and B-cell leukemia. It serves customers in the United States, Switzerland, and the United Kingdom.

Stock Analysis

last close $16.94
1-mo return -14.9%
3-mo return -33.3%
avg daily vol. 168.34T
52-week high 34.48
52-week low 16.35
market cap. $1.3B
forward pe -
annual div. -
roe -89.3%
ltg forecast 9.9%
dividend yield -
annual rev. $17M
inst own. 43.6%

Subscribe now for daily local and international financial news